Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Finds Statins Not Linked To ALS; When Can A False Alarm Be Turned Off?

Executive Summary

FDA's determination that statins do not increase the incidence of amyotrophic lateral sclerosis suggests that agency will continue to rely on data from placebo controlled trials to address concerns raised in post-marketing reports

You may also be interested in...

Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates

Agency responds to preliminary trial results by lifting the safety alert linking the inhaled anticholinergic to risk of stroke.

AstraZeneca’s Nexium, Prilosec Get Clean Bill Of Health From FDA

Agency says there is no evidence of either proton-pump inhibitor leading to cardiovascular risk.

Prilosec/Nexium Alert Is Debut Of FDA’s Early Communication Of Safety Issues

FDA's announcement of an ongoing safety investiation regarding a possible increased risk of cardiac events with AstraZeneca's Prilosec (omeprazole) and Nexium (esomeprazole) is the first test case of the agency's new policy of releasing emerging drug safety information

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts